{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T22:23:06Z","timestamp":1790893386656,"version":"4.1.0"},"reference-count":29,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,1]]},"abstract":"<jats:sec>\n                    <jats:title\/>\n                    <jats:p>Itraconazole, is the most commonly prescribed oral antifungal agent in India, and has a low minimum inhibitory concentration as compared to other oral antifungals, and in conjunction with the markedly high skin levels, the drug should have a predictably good clinical response which is not the consistent experience of clinicians. Probably the variation in pelletization parameters might affect the bioavailability of the drug and consequently affect the serum levels. The maximum bioavailability of conventional itraconazole is 55 percent, which is neither consistent nor predictable. However, the novel itraconazole (Super bioavailable Itraconazole) with targeted drug release in the small intestine has predictable serum levels with minimum interindividual variability, which could make it a potentially useful drug in recalcitrant dermatophytosis.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/idoj.idoj_618_20","type":"journal-article","created":{"date-parts":[[2021,11,16]],"date-time":"2021-11-16T09:15:00Z","timestamp":1637054100000},"page":"1-5","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":28,"title":["Super Bioavailable Itraconazole and Its Place and Relevance in Recalcitrant Dermatophytosis"],"prefix":"10.4103","volume":"12","author":[{"given":"Kabir","family":"Sardana","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sinu Rose","family":"Mathachan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R2-1-20240828","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1111\/myc.12772","article-title":"High terbinafine resistance in Trichophyton interdigitale isolates in Delhi, India harbouring mutations in the squalene epoxidase gene","volume":"61","author":"Singh","year":"2018","journal-title":"Mycoses"},{"key":"R3-1-20240828","doi-asserted-by":"crossref","first-page":"e01038","DOI":"10.1128\/AAC.01038-18","article-title":"Correlation of in vitro susceptibility based on MICs and squalene epoxidase mutations with clinical response to terbinafine in patients with tinea corporis\/cruris","volume":"62","author":"Khurana","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"R4-1-20240828","doi-asserted-by":"crossref","first-page":"e01964","DOI":"10.1128\/AAC.01964-19","article-title":"MIC and upper limit of wild-type distribution for 13 antifungal agents against a Trichophyton mentagrophytes-Trichophyton interdigitale complex of Indian origin","volume":"64","author":"Shaw","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"key":"R5-1-20240828","doi-asserted-by":"crossref","first-page":"103266","DOI":"10.1016\/j.fgb.2019.103266","article-title":"A unique multidrug-resistant clonal Trichophyton population distinct from Trichophyton mentagrophytes\/Trichophyton interdigitale complex causing an ongoing alarming dermatophytosis outbreak in India: Genomic insights and resistance profile","volume":"133","author":"Singh","year":"2019","journal-title":"Fungal Genet Biol"},{"key":"R6-1-20240828","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/myc.12865","article-title":"Perspectives on misidentification of Trichophyton interdigitale\/Trichophyton mentagrophytes using internal transcribed spacer region sequencing: Urgent need to update the sequence database","volume":"62","author":"Chowdhary","year":"2019","journal-title":"Mycoses"},{"key":"R7-1-20240828","doi-asserted-by":"crossref","first-page":"e02522","DOI":"10.1128\/AAC.02522-17","article-title":"Mutation in the squalene epoxidase gene of Trichophyton interdigitale and Trichophyton rubrum associated with allylamine resistance","volume":"62","author":"Rudramurthy","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"R8-1-20240828","doi-asserted-by":"crossref","first-page":"61","DOI":"10.4103\/ijdvl.IJDVL_715_17","article-title":"Reinterpreting minimum inhibitory concentration (MIC) data of itraconazole versus terbinafine for dermatophytosis-time to look beyond the MIC data?","volume":"84","author":"Khurana","year":"2018","journal-title":"Indian J Dermatol Venereol Leprol"},{"key":"R9-1-20240828","doi-asserted-by":"crossref","first-page":"678","DOI":"10.4103\/ijdvl.IJDVL_645_17","article-title":"A prospective study of the epidemiological and clinical patterns of recurrent dermatophytosis at a tertiary care hospital in India","volume":"84","author":"Pathania","year":"2018","journal-title":"Indian J Dermatol Venereol Leprol"},{"key":"R10-1-20240828","doi-asserted-by":"crossref","first-page":"436","DOI":"10.4103\/ijdvl.IJDVL_519_16","article-title":"Clinico-mycological study of dermatophytic infections and their sensitivity to antifungal drugs in a tertiary care center","volume":"83","author":"Mahajan","year":"2017","journal-title":"Indian J Dermatol Venereol Leprol"},{"key":"R11-1-20240828","doi-asserted-by":"crossref","first-page":"17","DOI":"10.3390\/jof3020017","article-title":"Molecular identification and antifungal susceptibility patterns of clinical dermatophytes following CLSI and EUCAST guidelines","volume":"3","author":"Dabas","year":"2017","journal-title":"J Fungi (Basel"},{"key":"R12-1-20240828","doi-asserted-by":"crossref","first-page":"e13633","DOI":"10.1111\/dth.13633","article-title":"A prospective study on patterns of topical steroids self-use in dermatophytoses and determinants predictive of cutaneous side effects","volume":"33","author":"Khurana","year":"2020","journal-title":"Dermatol Ther"},{"key":"R13-1-20240828","doi-asserted-by":"crossref","first-page":"103255","DOI":"10.1016\/j.fgb.2019.103255","article-title":"Antifungal resistance in dermatophytes: Recent trends and therapeutic implications","volume":"132","author":"Khurana","year":"2019","journal-title":"Fungal Genet Biol"},{"key":"R14-1-20240828","doi-asserted-by":"crossref","first-page":"730","DOI":"10.4103\/ijdvl.IJDVL_1012_16","article-title":"Intracutaneous pharmacokinetics of oral antifungals and their relevance in recalcitrant cutaneous dermatophytosis: Time to revisit basics","volume":"83","author":"Sardana","year":"2017","journal-title":"Indian J Dermatol Venereol Leprol"},{"key":"R15-1-20240828","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/S0190-9622(88)70037-7","article-title":"Pharmacokinetic profile of orally administered itraconazole in human skin","volume":"18","author":"Cauwenbergh","year":"1988","journal-title":"J Am Acad Dermatol"},{"key":"R16-1-20240828","doi-asserted-by":"crossref","first-page":"426","DOI":"10.4103\/idoj.IDOJ_339_17","article-title":"A pilot analysis of morphometric assessment of itraconazole brands using dermoscopy and its relevance in the current scenario","volume":"9","author":"Sardana","year":"2018","journal-title":"Indian Dermatol Online J"},{"key":"R17-1-20240828","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1080\/17512433.2019.1604218","article-title":"Parameters that determine dissolution and efficacy of itraconazole and its relevance to recalcitrant dermatophytoses","volume":"12","author":"Sardana","year":"2019","journal-title":"Expert Rev Clin Pharmacol"},{"key":"R19-1-20240828","doi-asserted-by":"crossref","first-page":"28","DOI":"10.3390\/jof6010028","article-title":"Aspiring antifungals: Review of current antifungal pipeline developments","volume":"6","author":"Gintjee","year":"2020","journal-title":"J Fungi (Basel"},{"key":"R20-1-20240828","doi-asserted-by":"crossref","first-page":"5681","DOI":"10.1128\/AAC.00973-15","article-title":"Population pharmacokinetic modeling of itraconazole and hydroxyitraconazole for oral SUBA-itraconazole and sporanox capsule formulations in healthy subjects in fed and fasted states","volume":"59","author":"Abuhelwa","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"R22-1-20240828","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1211\/0022357991772277","article-title":"Improving the oral bioavailability of albendazole in rabbits by the solid dispersion technique","volume":"51","author":"Kohri","year":"1999","journal-title":"J Pharm Pharmacol"},{"key":"R23-1-20240828","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1002\/jps.2600830425","article-title":"Improved oral absorption of enteric coprecipitates of a poorly soluble drug","volume":"83","author":"Kondo","year":"1994","journal-title":"J Pharm Sci"},{"key":"R24-1-20240828","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1007\/s11095-008-9543-1","article-title":"Targeted intestinal delivery of supersaturated itraconazole for improved oral absorption","volume":"25","author":"Miller","year":"2008","journal-title":"Pharm Res"},{"key":"R25-1-20240828","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1007\/s002280050438","article-title":"Effect of omeprazole on the pharmacokinetics of itraconazole","volume":"54","author":"Jaruratanasirikul","year":"1998","journal-title":"Eur J Clin Pharmacol"},{"key":"R26-1-20240828","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1002\/(SICI)1099-1069(1998030)16:1<33::AID-HON620>3.0.CO;2-9","article-title":"Plasma concentration of itraconazole in patients receiving chemotherapy for hematological malignancies: The effect of famotidine on the absorption of itraconazole","volume":"16","author":"Kanda","year":"1998","journal-title":"Hematol Oncol"},{"key":"R27-1-20240828","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1111\/j.1365-2710.2005.00632.x","article-title":"Reduced oral itraconazole bioavailability by antacid suspension","volume":"30","author":"Lohitnavy","year":"2005","journal-title":"J Clin Pharm Ther"},{"key":"R28-1-20240828","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1182\/blood-2003-08-2644","article-title":"Itraconazole versus fluconazole for prevention of fungal infections in patients receiving allogeneic stem cell transplants","volume":"103","author":"Marr","year":"2004","journal-title":"Blood"},{"key":"R29-1-20240828","doi-asserted-by":"crossref","first-page":"e01723","DOI":"10.1128\/AAC.01723-18","article-title":"Effects of food and omeprazole on a novel formulation of super bioavailability itraconazole in healthy subjects","volume":"62","author":"Lindsay","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"R30-1-20240828","doi-asserted-by":"crossref","first-page":"3414","DOI":"10.1093\/jac\/dkx295","article-title":"Serum levels, safety and tolerability of new formulation SUBA-itraconazole prophylaxis in patients with haematological malignancy or undergoing allogeneic stem cell transplantation","volume":"72","author":"Lindsay","year":"2017","journal-title":"J Antimicrob Chemother"},{"key":"R31-1-20240828","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1007\/s00228-006-0200-5","article-title":"Comparative analysis of the effects of rice and bread meals on bioavailability of itracona- zole using NONMEM in healthy volunteers","volume":"62","author":"Yun","year":"2006","journal-title":"Eur J Clin Pharmacol"},{"key":"R32-1-20240828","first-page":"87","article-title":"Influence of concomitant food intake on the gastrointestinal absorption of fluconazole and itraconazole in Japanese subjects","volume":"14","author":"Zimmermann","year":"1993","journal-title":"Int J Clin Pharmacol Res"}],"container-title":["Indian Dermatology Online Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/idoj.IDOJ_618_20","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T19:11:13Z","timestamp":1787771473000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/idoj.IDOJ_618_20"}},"subtitle":["Revisiting Skin Levels of Itraconazole and Minimum Inhibitory Concentration Data"],"short-title":[],"issued":{"date-parts":[[2021,1]]},"references-count":29,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.4103\/idoj.idoj_618_20","relation":{},"ISSN":["2229-5178"],"issn-type":[{"value":"2229-5178","type":"print"}],"subject":[],"published":{"date-parts":[[2021,1]]}}}